Korea Arlico Pharm Co.,Ltd. (260660.KQ)

4,885.00 -5.00 (-0.10%) At close: 03:30PM KST

Korea Arlico Pharm Co.,Ltd.

Alico Pharmaceutical Building
7-21 Baumoe-ro 27- gil Seocho-gu
Seoul
South Korea
82 2 585 0004
https://www.arlico.co.kr

Sector(s): 
Industry: 
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Hang-Gu Lee	Chief Executive Officer	N/A	N/A	1961

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. It offers ETC, OTC, medical device, and other products; and active ingredients. The company provides products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. was founded in 1992 and is headquartered in Seoul, South Korea.

Corporate Governance

Korea Arlico Pharm Co.,Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.